Price
$0.6821
Increased by +1.05%
Dollar Volume (20D)
9.75 M
ADR%
14.38
Earnings Report Date (estimate)
Mar 12, 24
Shares Float
319.46 M
Shares Outstanding
381.5 M
Shares Short
43.85 M
Market Cap.
260.22 M
Beta
1.27
Price / Earnings
N/A
20D Range
0.57 0.95
50D Range
0.53 0.95
200D Range
0.53 2.13
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 7, 23 -0.16
Increased by +15.79%
-0.19
Increased by +15.79%
Aug 8, 23 -0.2
Decreased by -17.65%
-0.2
May 9, 23 -0.22
Decreased by -15.79%
-0.21
Decreased by -4.76%
Mar 14, 23 -0.24
Increased by +7.69%
-0.22
Decreased by -9.09%
Nov 8, 22 -0.19
Decreased by -127.54%
-0.19
Aug 9, 22 -0.17
Increased by +54.05%
-0.23
Increased by +26.09%
May 10, 22 -0.19
Increased by +29.63%
-0.3
Increased by +36.67%
Mar 1, 22 -0.26
Decreased by -30%
-0.16
Decreased by -62.5%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 23 24.31 M
Increased by +6.77%
-62.2 M
Increased by +16.26%
Decreased by -255.82%
Increased by +21.57%
Jun 30, 23 25.3 M
Increased by +20.88%
-73.43 M
Decreased by -43.69%
Decreased by -290.28%
Decreased by -18.86%
Mar 31, 23 22.9 M
Decreased by -11.72%
-67.85 M
Decreased by -6.9%
Decreased by -296.25%
Decreased by -21.09%
Dec 31, 22 28.39 M
Increased by +40.1%
-97.4 M
Decreased by -48.67%
Decreased by -343.12%
Decreased by -6.12%
Sep 30, 22 22.77 M
Decreased by -91%
-74.28 M
Decreased by -141.6%
Decreased by -326.18%
Decreased by -562.1%
Jun 30, 22 20.93 M
Increased by +95.02%
-51.1 M
Increased by +38.64%
Decreased by -244.21%
Increased by +68.54%
Mar 31, 22 25.94 M
Increased by +121.36%
-63.47 M
Decreased by -18.24%
Decreased by -244.66%
Increased by +46.58%
Dec 31, 21 20.26 M
Decreased by -35.19%
-65.51 M
Decreased by -74.2%
Decreased by -323.34%
Decreased by -168.8%
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 2 clinical trial; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; BMS-986442, a TIGIT bispecific antibodies; and AGEN1327, a human monoclonal antibody. In addition, it develops INCAGN1876, a GITR monospecific antibody; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; AGENT 797, an iNKT cells that is in Phase 1 clinical trial for solid tumors, multiple myeloma, and viral ARDS; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.